Compare GSK plc (GSK) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Oracle Corporation — how do they compare? GSK plc trades at $46.6 (market cap $91.88B), while Oracle Corporation trades at $141.64 (market cap $411.34B). The key difference: Oracle Corporation is far larger — about 4.5× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Oracle Corporation for 72 Days on average.
| GSK | ORCL | |
|---|---|---|
Market Cap | $91.88B | $411.34B |
Volume | 7,730,529 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $61.18 | $313.00 |
52-Week Low | $43.24 | $114.99 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $111.88B | $535.15B |
Dividend Yield | 3.9% | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Oracle (ORCL) trades at $143.56, down 0.83% amid a bearish technical signal, though recent earnings consistently beat expectations with Q2 2026 EPS of $1.92 versus $1.74 expected. The company shows strong fundamentals with 2025 revenue of $57.40B and net income margin of 26.36%, while analyst consensus remains bullish with a $236.52 price target. News highlights AI cloud growth of 120% in Q1 2026 but also layoffs and market concerns over AI spending cycles.
The outlook is mixed: robust AI-driven revenue growth and high profitability support upside, but technical weakness and macroeconomic risks like Fed policy pose near-term headwinds. Investors face opportunity from AI demand against volatility from high debt and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
